-
Mashup Score: 3Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Although digital breast tomosynthesis (DBT; 3D mammography) was approved by the U.S. Food and Drug Administration a decade ago and has since…
Source: commonsensemd.blogspot.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Premature adoption of 3D mammography threatens study that aims to prove its value: Although digital breast tomosynthesis was approved by @US_FDA a decade ago and has since been rapidly adopted by breast imaging centers, no studies have shown ... https://t.co/zsqZGYwpKE #TMIST
-
-
Mashup Score: 0
publication date: Mar. 19, 2021By Paul GoldbergAn ad hoc group formed by NCI to provide advice on the slowly-accruing TMIST—Tomosynthesis Mammographic Imaging Screening Trial—recommended that the trial be streamlined, but should continue.The panel presented its report to the Clinical Trials and Translational Research Advisory Committee on March 17, and the committee voted unanimously to accept…
Source: cancerletter.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An ad hoc group evaluating @theNCI/@eaonc's #TMIST said that a comparison of two-dimensional and three-dimensional mammography can be best answered in a randomized controlled trial. #BCSM https://t.co/oLFV9HwGxJ https://t.co/B5fr18348V
-
-
Mashup Score: 0Facebook - 4 year(s) ago
Sidney Kimmel Cancer Center – Jefferson Health 4 hrs The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is a randomized breast cancer screening study. TMIST is important to the future of breast cancer screening because it will help provide knowledge about how to move beyond a current “one size fits all” approach, where most women are screened the same way based on age-specific…
Source: www.facebook.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The Tomosynthesis Mammographic Imaging Screening Trial (#TMIST) is a randomized #breastcancer screening study from @eaonc that is currently available at Jefferson. Learn more: https://t.co/c3vv5iNtEu #cancerscreening #bcam #bcsm #clinicaltrial #mammography https://t.co/jyfrnIphQl
-
-
Mashup Score: 3Mitch Schnall: “We don’t want to lose momentum as this review is happening” – The Cancer Letter - 4 year(s) ago
publication date: Sep. 11, 2020Conversation with The Cancer LetterMitchell D. Schnall MD, PhDGroup co-chair, ECOG-ACRIN Cancer Research Group;Eugene P. Pendergrass Professor of Radiology, The Perelman School of Medicine, University of PennsylvaniaNCI’s publicly announced move to create an ad hoc working group that would review the feasibility and viability of the TMIST trial threatens to…
Source: cancerletter.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@eaonc & @PennMedicine's Mitchell Schnall on the uncertain future of #TMIST: ""My hope is that we’ll get support from @theNCI enough that we can continue to have the momentum that we have." https://t.co/GuRo5vwKC7 https://t.co/doQVKMGSkK
-
-
Mashup Score: 3
publication date: Sep. 11, 2020Guest EditorialOn behalf of the ECOG-ACRIN Cancer Research GroupEtta D. Pisano, MDPrincipal investigator, TMIST;Professor in Residence of Radiology,Beth Israel Deaconess Medical CenterConstantine A. Gatsonis, PhDHenry Ledyard Goddard University Professor of Biostatistics,Chair, Department of Biostatistics, Brown UniversityPeter J. O’Dwyer, MDGroup co-chair,…
Source: cancerletter.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Toward individualized #breastcancer screening strategies—#TMIST. Guest editorial from @eaonc's Pisano, Gatsonis, O'Dwyer, & Schnall. — https://t.co/R6e58oWdxG https://t.co/ViEPzTfEJC
-
-
Mashup Score: 1
publication date: Sep. 11, 2020The future of ECOG-ACRIN’s slowly-accruing TMIST is in question By Paul GoldbergNCI’s cancer screening trials may be falling victim to the COVID-19 pandemic.Last week, the institute asked the National Cancer Advisory Board to form an ad hoc group that would provide guidance on screening trials, starting with the Tomosynthesis Mammographic Imaging Screening Trial,…
Source: cancerletter.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@theNCI will form an ad hoc committee to review screening trials. The future of @eaonc’s slowly-accruing #TMIST is in question. — https://t.co/KN12VuSFaJ https://t.co/n7Tw42ycv6
-
Since 2017, researchers at @eaonc have focused on the #3DMammogram's ability to detect #bcsm that lead to more women's deaths. To accurately gage this, researchers are asking women of color and imaging centers in underserved areas to participate in #TMIST: https://t.co/Hk1EWFiM4s https://t.co/DP9VDQkLFA